PNC Financial Services Group Inc. reduced its position in shares of USANA Health Sciences Inc. (NYSE:USNA) by 50.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,837 shares of the company’s stock after selling 1,851 shares during the period. PNC Financial Services Group Inc.’s holdings in USANA Health Sciences were worth $204,000 as of its most recent filing with the SEC.
Other large investors have also recently made changes to their positions in the company. Glenmede Trust Co. NA bought a new position in USANA Health Sciences during the second quarter worth approximately $349,000. Palo Capital Inc. bought a new position in USANA Health Sciences during the second quarter worth approximately $394,000. AMP Capital Investors Ltd increased its position in USANA Health Sciences by 108.5% in the first quarter. AMP Capital Investors Ltd now owns 3,459 shares of the company’s stock worth $413,000 after buying an additional 1,800 shares during the period. Invictus RG increased its position in USANA Health Sciences by 9,678.4% in the first quarter. Invictus RG now owns 3,618 shares of the company’s stock worth $439,000 after buying an additional 3,581 shares during the period. Finally, Huntington Asset Advisors Inc. bought a new position in USANA Health Sciences during the first quarter worth approximately $443,000. 41.86% of the stock is currently owned by institutional investors.
Shares of USANA Health Sciences Inc. (NYSE:USNA) traded down 0.31% on Wednesday, reaching $142.65. 47,753 shares of the company’s stock traded hands. The company has a 50 day moving average of $136.66 and a 200-day moving average of $126.04. The stock has a market capitalization of $1.72 billion, a PE ratio of 18.80 and a beta of 1.34. USANA Health Sciences Inc. has a 52 week low of $92.00 and a 52 week high of $144.40.
USANA Health Sciences (NYSE:USNA) last posted its earnings results on Tuesday, July 26th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $2.05 by $0.02. USANA Health Sciences had a net margin of 10.07% and a return on equity of 34.15%. The business had revenue of $258.50 million for the quarter, compared to analysts’ expectations of $256.66 million. During the same period in the previous year, the company posted $1.92 earnings per share. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. Equities research analysts forecast that USANA Health Sciences Inc. will post $8.10 earnings per share for the current year.
A number of research analysts recently commented on the stock. Zacks Investment Research downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, September 28th. DA Davidson increased their target price on shares of USANA Health Sciences from $135.00 to $150.00 and gave the company a “neutral” rating in a research report on Thursday, July 28th. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. USANA Health Sciences presently has a consensus rating of “Buy” and a consensus target price of $149.11.
In related news, insider Deborah Woo sold 1,058 shares of the company’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $140.00, for a total value of $148,120.00. Following the sale, the insider now directly owns 2,537 shares of the company’s stock, valued at $355,180. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Global Ltd Gull sold 10,000 shares of the company’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $134.67, for a total transaction of $1,346,700.00. Following the completion of the sale, the insider now directly owns 6,329,110 shares in the company, valued at $852,341,243.70. The disclosure for this sale can be found here. Insiders own 57.00% of the company’s stock.
About USANA Health Sciences
USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. It operates as a direct selling company in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions: Southeast Asia Pacific, Greater China and North Asia.
Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences Inc. (NYSE:USNA).
Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.